EU Food Safety Agency Sets Strict Daily Limit for Hemp-Derived CBD in Food Supplements

February 10, 2026

PARMA, Italy — The European Food Safety Authority (EFSA) has established a formal safe intake level for hemp-derived cannabidiol (CBD) for the first time, recommending that healthy adults consume no more than 2 mg per day.

This provisional threshold, announced by the agency’s expert Panel on Nutrition, Novel Foods and Food Allergens, is significantly lower than guidelines in neighboring regions. The decision reflects deep-seated regulatory concerns over “lingering gaps” in long-term safety data regarding CBD’s impact on the liver, nervous system, and reproductive health. By setting this limit, the EU has created a sharp regulatory divide with the United Kingdom, Switzerland, and Canada, signaling a highly cautious approach to one of the world’s most popular wellness supplements.

Defining the “Provisional” Limit: 2 mg Per Day

The new guidance specifies a daily intake of 0.0275 mg per kilogram of body weight. For a typical adult weighing 70 kg (approximately 154 lbs), this rounds to roughly 2 mg of CBD per day.

It is important to note that EFSA classifies this as a provisional acceptable daily intake (ADI). This means the number is not permanent; it serves as a conservative “placeholder” while the scientific community gathers more robust toxicology data.

What Products Are Affected?

The 2-mg limit is specifically targeted at high-purity food supplements, such as:

• Concentrated oils and tinctures

• Capsules and powders

• Gummies and isolates (typically ≥98% purity)

Products that must meet this standard are those processed to ensure they do not contain nanoparticles and have been cleared of “genotoxic risk”—the potential to damage human DNA. Interestingly, CBD-infused foods like honey, tea, or snacks often contain trace amounts that already fall well below this new threshold, making the supplement market the primary focus of this crackdown.

The Science of Caution: Why the EU is Moving Slowly

While CBD is non-intoxicating and does not produce the “high” associated with THC (tetrahydrocannabinol), it is still a pharmacologically active compound. EFSA’s conservative stance stems from a lack of long-term “curves” showing how the compound affects healthy humans over years of use.

Current clinical data, largely derived from high-dose prescription CBD used to treat rare forms of epilepsy, has highlighted several areas of concern:

1. Liver Health: Observations of transient increases in liver enzymes, which can indicate stress or damage to the organ.

2. Drug Interactions: CBD is metabolized by the liver in a way that can interfere with how the body processes other prescription medications.

3. Hormonal Systems: Incomplete data on how chronic use affects the endocrine and reproductive systems.

Because of these uncertainties, EFSA has applied a “safety factor” roughly 400-fold below the level where no adverse effects were observed in animal studies. Furthermore, the agency stated there is currently no safe level of CBD intake for:

• Individuals under the age of 25

• Pregnant or breastfeeding women

• Anyone currently taking prescription medications

Expert Perspectives: Safety vs. Utility

The move has sparked a debate between public health advocates and industry proponents.

“This is a classic precautionary-model approach,” says Dr. Anya Petrova, a clinical pharmacologist at a European teaching hospital. “For the average consumer, this sends a clear message: CBD is not a vitamin. It is a compound that carries real risks of side effects and drug interactions.”

However, some industry analysts worry the limit is too low. Critics argue that a 2-mg ceiling may lead to “micro-dosing” products that provide no therapeutic benefit at all, potentially misleading consumers who are seeking relief from anxiety or insomnia.

“There is no basis yet in EU-level science for seeing CBD as a vitamin-like supplement that is somehow safe at almost any dose,” Dr. Petrova added.

A Global Regulatory Patchwork

The EU’s new limit places it at the restrictive end of the global spectrum. For comparison:

• United Kingdom: The Food Standards Agency (FSA) recommends a maximum of 10 mg/day.

• Switzerland/Canada: These nations allow higher doses, often under the guidance of a pharmacist or for limited durations.

Practical Implications: What Consumers Should Do

For those who currently use CBD, the EFSA move suggests it may be time to audit your dosage. Public health authorities emphasize that CBD is not a substitute for evidence-based medical treatment for chronic pain or mental health conditions.

Consumer Checklist:

• Read the Label: Calculate the total milligrams of CBD per serving. Many standard gummies contain 10 mg to 25 mg—five to ten times the new EU limit.

• Disclose Usage: Always tell your doctor or pharmacist if you are taking CBD, as it can change how your other medications work.

• Check Purity: Prioritize products with third-party lab testing to ensure they are free from contaminants or illegal levels of THC.

• Identify Your Group: If you are under 25, pregnant, or on medication, the current EU guidance suggests avoiding CBD supplements entirely.

The Road Ahead

This 2-mg limit will now serve as the benchmark for national regulators across the EU when deciding which “novel food” applications to approve. Companies wishing to sell higher-dose products will likely be required to submit more extensive, expensive safety dossiers to prove their products do not pose a long-term risk.

As research continues, the “provisional” nature of this limit means the door remains open for change. For now, however, the era of the high-dose, unregulated CBD supplement in Europe appears to be coming to a close.

References

• European Food Safety Authority (EFSA). “Provisional safe level for cannabidiol as a novel food – news release.” Feb 8, 2026. efsa.europa.eu

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.